Drug intelligence / Profile preview

hepatitis a vaccine (inactivated, HM175 strain)

Development stage
Approved
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Hepatitis a vaccine (inactivated, HM175 strain) is an **inactivated viral vaccine** developed by **GSK** and marketed as **Havrix** for active immunization against hepatitis A virus infection. The vaccine contains **formaldehyde-inactivated hepatitis A virus strain HM175** produced in **MRC-5 human diploid cells**, purified and adsorbed to an aluminum-based adjuvant, and is administered to induce protective anti-HAV antibody responses. It is indicated for prevention of hepatitis A disease in individuals **12 months of age and older**, with marketed pediatric and adult dose strengths, and clinical studies showed high seroconversion after the first dose and protective efficacy of about 95%.

Brand names
Havrix
Other names
hepatitis a vaccine (inactivated, HM175 strain)inactivated hepatitis a virus vaccinehepatitis a vaccine inactivated

Beyond the preview

Go deeper on hepatitis a vaccine (inactivated, HM175 strain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepatitis a vaccine (inactivated, HM175 strain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call